QuickVue Influenza/SARS-CoV 2 Test (25/bx)

• Rapid Detection of Influenza A, Influenza B & SARS-CoV-2
• Provides Results in Approximately 10 Minutes
• Uses Direct Anterior Nasal Swab Specimens
• Includes 25 Complete Tests per Kit
• Designed for Professional In Vitro Diagnostic Use .

The Quidel QuickVue Influenza/SARS-CoV 2 Test is a rapid lateral flow immunoassay intended for the qualitative detection of Influenza A, Influenza B, and SARS-CoV-2 antigens from direct anterior nasal swab specimens collected from individuals with signs and symptoms of respiratory infection. Delivering results in approximately 10 minutes, the test provides healthcare professionals with a convenient point-of-care solution for rapid respiratory virus detection.

✔ MULTIPLEX RESPIRATORY TESTING | ✔ RAPID 10-MINUTE RESULTS | ✔ SIMPLE POINT-OF-CARE WORKFLOW

FAST & ACCURATE RESPIRATORY DETECTION

• QUALITATIVE DETECTION: Detects Influenza A antigen, Influenza B antigen, and SARS-CoV-2 nucleocapsid antigen from a single direct anterior nasal swab specimen, providing separate qualitative results for each target.
• RAPID RESULTS: Produces test results in approximately 10 minutes, supporting timely clinical evaluation and patient management.
• LATERAL FLOW IMMUNOASSAY: Utilizes lateral flow immunoassay technology for the qualitative detection of Influenza A antigen, Influenza B antigen, and SARS-CoV-2 nucleocapsid antigen.

STREAMLINED POINT-OF-CARE TESTING

• SINGLE-SPECIMEN TESTING: Uses one direct anterior nasal swab specimen to evaluate three common respiratory viruses, simplifying specimen collection and testing.
• 25-TEST KIT: Each kit contains materials required to perform 25 tests, making it suitable for physician offices, urgent care centers, clinics, and clinical laboratories.
• ROOM TEMPERATURE STORAGE: Test components are stored at room temperature according to the manufacturer's storage recommendations, simplifying inventory management.

The Quidel QuickVue Influenza/SARS-CoV 2 Test provides healthcare professionals with a rapid and convenient solution for the qualitative detection of Influenza A, Influenza B, and SARS-CoV-2, supporting timely diagnosis and appropriate clinical decision-making during respiratory illness seasons.

**FDA Disclaimer: This combination test is not FDA cleared or approved, but only authorized under an Emergency Use Authorization for use by authorized laboratories. It is authorized for the rapid detection of proteins from SARS-CoV-2, Influenza A and B, and not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for the detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

WARNING: This product can expose you to chemicals known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.